<DOC>
	<DOCNO>NCT01712412</DOCNO>
	<brief_summary>The objective study determine safety efficacy IW-9179 administer patient functional dyspepsia ( FD ) .</brief_summary>
	<brief_title>Phase 2a Study IW-9179 Treat Functional Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>Patient meet ROME III criterion functional dyspepsia ( FD ) Patient normal esophagogastroduodenoscopy ( EGD ) either Screening Period within 2 year Screening Visit Patients EITHER : 1 . Have use proton pump inhibitor ( PPI ) within 4 week Screening Visit , OR 2 . Have use PPI stable dose least 4 week prior Screening Visit ; Patient meet symptom severity criterion Pretreatment Period Patient fluent literate Dutch , French , English Patient meet criteria gastroesophageal reflux disease ( GERD , stable regimen PPIs acceptable ) , constipation , diarrhea , low abdominal pain , gastroparesis Patient history inflammatory bowel disease , chronic pancreatitis , small intestinal bacterial overgrowth , celiac disease , lactose intolerance , polycystic kidney disease , interstitial cystitis , scleroderma Any significant neurological disease history cancer ( resect basal cell squamous cell carcinoma skin acceptable ; complete remission cancer 5 year longer also acceptable ) History active alcoholism drug addiction within 12 month prior Screening Visit Hospitalized psychiatric condition make suicide attempt two year Screening Visit Any organic structural disease cause abdominal pain discomfort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>